Bandingkan Harga & Kinerja Fortune Mate Indonesia Tbk (FMII) vs Organon Pharma Indonesia Tbk. (SCPI)
Kinerja harga (24 Jam Terakhir)
Statistik utama
Statistik utama
Perbedaan Fortune Mate Indonesia Tbk dan Organon Pharma Indonesia Tbk.: Fortune Mate Indonesia Tbk diperdagangkan di Rp254 (kapitalisasi pasar 1,63 T, volume 24 jam 5,8 rb), sedangkan Organon Pharma Indonesia Tbk. diperdagangkan di Rp29.000 (kapitalisasi pasar 104,4 M). Perbedaan utamanya: Fortune Mate Indonesia Tbk jauh lebih besar — sekitar 15,6× kapitalisasi pasar Organon Pharma Indonesia Tbk.. Mana yang lebih baik tergantung tujuan investasimu.
| FMII | SCPI | |
|---|---|---|
Kapitalisasi Pasar | 1,63 T | 104,4 M |
Volume | 5,8 rb | — |
Lot | 58 | — |
Perputaran | 1,45 jt | — |
Harga Rata-rata | 249,52 | — |
Nilai Transaksi | 1,45 jt | — |
Harga Ekuilibrium Indikatif | 254 | — |
Volume Ekuilibrium Indikatif | 1 | — |
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Berita terkini
Berita terbaru kedua aset
Berita terkini
Berita terbaru kedua aset
Tentang Fortune Mate Indonesia Tbk
PT Fortune Mate Indonesia Tbk (the Entity) was established within the framework of the Foreign Capital Investment Law (PMA) No. 1 year 1967 based on Notarial Deed No. 44 dated June 24, 1989 by Rika You Soo Shin, S.H., notary in Surabaya. The Entity has started its commercial operations since 1989 comprises the manufacturing of footwear were located in Sidoarjo, East Java and stopped its operation since middle of March 2004. The Entity's office and real estate are located in Surabaya.
Selengkapnya di halaman FMII →Tentang Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Selengkapnya di halaman SCPI →
